NCT03772535
Unknown
Phase 3
Using Pharmacogenetics to Structure Individual Pain Management Protocols for Joint Replacement Patients
ConditionsArthroplasty Complications
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- Arthroplasty Complications
- Sponsor
- Anderson Orthopaedic Research Institute
- Enrollment
- 50
- Locations
- 1
- Primary Endpoint
- Genetic variants
- Last Updated
- 5 years ago
Overview
Brief Summary
The purpose of this study is to determine the ability to use pharmacogenetic testing in a joint replacement practice to prescribe the most effective pain medicine for a specific patient.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Primary total hip or total knee arthroplasty cases
Exclusion Criteria
- •History of narcotic dependence
Outcomes
Primary Outcomes
Genetic variants
Time Frame: 10 days postoperative
Percent of subject with genetic variants affecting pain medication
Secondary Outcomes
- pain levels(10 days postoperatively)
Study Sites (1)
Loading locations...
Similar Trials
Unknown
Not Applicable
Pharmacogenetic Study of Warfarin Dose-Response: a Prospective TrialCardiovascular DiseasesNCT00654823Sheba Medical Center500
Unknown
Not Applicable
Pharmacogenetic Algorithm for Individualized Controlled Ovarian StimulationInfertilityNCT03149536Clínica Origen1,350
Recruiting
Not Applicable
Personalized Pharmacotherapy Using Pharmacogenetics in VeteransPharmacogenetic Testing to Determine Pharmacological Treatment in PTSDNCT06335043London Health Sciences Centre OR Lawson Research Institute of St. Joseph's155
Completed
Not Applicable
Implementation of Pharmacogenetic Testing in Hospital WardsAdmitted Multimorbid PatientsNCT04573491Hospital Pharmacy Enterprise, South Eastern Norway46
Completed
Not Applicable
Pharmacogenomic Analysis of Samples From Subjects in Study RN1004-0082WoundNCT00663780Renovo195